1stOncology™: Cancer Intelligence Service – Page 14240 – 1stOncology is recognized as a Top 10 Global Pharma Analytic Provider

MannKind Corporation Participating at Upcoming Conferences

On February 20, 2019 MannKind Corporation (Nasdaq: MNKD), a company focused on the development and commercialization of inhaled therapeutic products for patients with diseases such as diabetes and pulmonary arterial hypertension, reported that it will be participating at upcoming conferences (Press release, Mannkind, FEB 20, 2019, View Source [SID1234533500]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

Schedule Your 30 min Free Demo!

8th Annual SVB Leerink Global Healthcare Conference on Wednesday, February 27, 2019 at 9:00 am (ET) at the Lotte New York Palace, New York, NY. Presenting from the Company will be its Chief Executive Officer, Michael Castagna, PharmD. Interested parties can access a link to the live webcast of the presentation from the News & Events section of the Company’s website at View Source

BTIG MedTech, Life Science & Diagnostic Tools 2019 Conference February 26-28, 2019 in Snowbird, UT. Participating from the Company will be its Chief Financial Officer, Steven B. Binder, and Chief Commercial Officer, Patrick McCauley in one-on-one meetings connecting management with institutional investors.

Intrexon’s Subsidiary Precigen to Present at the SVB Leerink 8th Annual Global Healthcare Conference

On February 20, 2019 Intrexon Corporation (NASDAQ: XON), a leader in the engineering and industrialization of biology to improve the quality of life and health of the planet, and its wholly-owned subsidiary Precigen, Inc., a biopharmaceutical company specializing in the development of innovative gene and cellular therapies to improve the lives of patients, reported their presentation at the SVB Leerink 8th Annual Global Healthcare Conference in New York (Press release, Intrexon, FEB 20, 2019, View Source [SID1234533499]. Helen Sabzevari, PhD, president of Precigen, will present on Thursday, February 28, 2019 at 11:30 am Eastern Time.

Investors, analysts, media and other interested parties may participate in the event at 11:30 am Eastern Time via live audio webcast, which can be accessed through Intrexon’s website in the Investors section under ‘Events’ at investors.dna.com/events and on Precigen’s website under ‘Presentations’ at www.precigen.com/media/#id-presentations. The presentation will be archived on the Intrexon and Precigen websites following the presentation.

Audentes Therapeutics to Participate in Upcoming Investor Conferences

On February 20, 2019 Audentes Therapeutics, Inc. (Nasdaq: BOLD), a biotechnology company focused on developing and commercializing innovative gene therapy products for patients living with serious, life-threatening rare diseases, reported that it will participate in the following investor conferences in February and March (Press release, Audentes Therapeutics, FEB 20, 2019, View Source [SID1234533498]):

8th Annual SVB Leerink Global Healthcare Conference Natalie Holles, President and Chief Operating Officer Format: Fireside ChatThursday, February 28, 2019, at 9:30 am ETNew York, New York
Cowen 39th Annual Health Care Conference Matthew R. Patterson, Chairman and Chief Executive Officer Format: Corporate Presentation Tuesday, March 12, 2019, at 11:20 am ET Boston, Massachusetts
To access live webcasts of the fireside chat and presentation, please visit the Events & Presentations page within the Investors + Media section of the Audentes website. Following each conference, a replay of the live webcast will be available on the Audentes website for approximately 30 days.

VBL Therapeutics Awarded $2.9 Million Non-Dilutive Grant by the Israel Innovation Authority

On February 20, 2019 VBL Therapeutics (Nasdaq: VBLT) (the "Company") reported that it has been awarded a non-dilutive grant of over 10 million New Israeli Shekels (approximately $2.9 million) by the Israel Innovation Authority (IIA) for 2019 (Press release, VBL Therapeutics, FEB 20, 2019, View Source [SID1234533496]). The funds will support the continued development of the Company’s lead product candidate, VB-111, a first-in-class targeted anti-cancer gene-therapy agent. The Company is currently evaluating VB-111 in a potential registration study (OVAL) for the treatment of platinum-resistant ovarian cancer, with further plans to study VB-111 in additional solid tumor indications.

"We are appreciative of the continued substantial support by the IIA of our VB-111 program, which is a vote of confidence in our lead product candidate and its clinical and market potential," said Prof. Dror Harats, Chief Executive Officer of VBL Therapeutics. "This $2.9 million grant, combined with the more than $53 million in cash on our balance sheet at September 30, 2018, will support our continued development of VB-111 and our other pipeline candidates, including our MOSPD2 programs in oncology and inflammation, through late 2021."

About the Israel Innovation Authority
The Israel Innovation Authority is an independent and impartial public entity that operates for the benefit of the Israeli innovation ecosystem and the country’s economy. For more information, refer to View Source

CymaBay Therapeutics to Present at the 8th Annual SVB Leerink Global Healthcare Conference

On February 20, 2019 CymaBay Therapeutics, Inc. (NASDAQ: CBAY), a clinical-stage biopharmaceutical company focused on developing therapies for liver and other chronic diseases with high unmet need, reported that management will participate in a fireside chat at the 8th Annual SVB Leerink Global Healthcare Conference in New York, NY (Press release, CymaBay Therapeutics, FEB 20, 2019, View Source [SID1234533495]). The presentation will begin at 10:30 a.m. Eastern Time on Wednesday, February 27, 2019.

A live audio webcast of the presentation can be accessed through the Investors section of the CymaBay Therapeutics corporate website at View Source The webcast will be archived on the corporate website for 90 days.